SPRY
ARS Pharmaceuticals·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 3
Bearish signal 1
Consensus Rating "Strong Buy"
Ample Liquidity
High Gross Profit Margin
Significant Net Income Decline
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About SPRY
Ars Pharmaceuticals, Inc.
A clinical-stage biopharmaceutical company developing innovative treatments for severe allergic reactions
11682 El Camino Real, Suite 120, San Diego, California 92130
--
ARS Pharmaceuticals, Inc., was incorporated under the laws of the State of Delaware on January 4, 2016. The company is a biopharmaceutical company focused on developing novel, potentially best-in-class product candidates, neffy for the emergency treatment of type I allergic reactions, including anaphylaxis. Neffy is a proprietary composition of epinephrine with an innovative absorption enhancer called Intravail that allows neffy to deliver injection-like epinephrine absorption in small doses, easy to carry, easy to use, fast to administer and reliable nasal sprays.
Earnings Call
Q1/2025
Estimate EPS-0.36
Actual EPS-0.35
Estimate Revenue7.48M
Actual Revenue7.97M
ARS Pharmaceuticals Q1 2025: Navigating Contradictions in Payer Coverage, Market Share, and Sales Targets
May 20,2025 09:11
Earnings Decrypt
Earnings Decrypt
Q2/2025
Estimate EPS-0.51
Actual EPS-0.46
Estimate Revenue13.78M
Actual Revenue15.72M
ARS Pharmaceuticals' Q2 2025: Navigating Key Contradictions in DTC Impact, Inventory, and NUCLEUS Commercialization
Aug 13,2025 12:02
Earnings Decrypt
Earnings Decrypt
Company Financials
EPS
SPRY has released its 2025 Q3 earnings. EPS was reported at -0.52, versus the expected -0.49, missing expectations. The chart below visualizes how SPRY has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
SPRY has released its 2025 Q3 earnings report, with revenue of 32.50M, reflecting a YoY change of 1471.62%, and net profit of -51.15M, showing a YoY change of -167.41%. The Sankey diagram below clearly presents SPRY's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
